Kyntra Bio Inc. (KYNB)
KYNB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/921299/000119312526108346/0001193125-26-108346-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | KYNB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0000921299 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $6.4M |
| Net income | $183.5M |
| Operating income | -$45.9M |
| Net margin | 2848.6% |
| Operating margin | -712.7% |
| Revenue growth | -78.3% |
| Cash | $47.9M |
| Total assets | $119.6M |
| P/E (computed) | 0.1× |
| P/S (computed) | 2.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-13 |
| Cash and burn | $50.6M cash; operating cash flow -$9.5M a quarter. | Report 2026-06-30 |
| Shares outstanding | 4,049,124 (2026-07-31); 4,043,899 a year earlier; 98,210,168 three years earlier. 3y figure adjusted for split (1-for-25 overall). | Cover page 2026-07-31 |
| Reverse splits, 3 years | 1; latest 1-for-25 on 2025-06-17 | Source 2025-06-17 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-10-06 |
| Auditor | PricewaterhouseCoopers LLP, Irvine, California, United States | PCAOB Form AP 2026-03-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $54K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | -$1.5M | $12.0M | -$4.0M | $50.6M | No debt tags | $4.6M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $3.7M | -$15.2M | -$13.9M | $37.0M | No debt tags | $7.4M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $1.3M | -$14.2M | -$18.3M | $47.9M | No debt tags | $6.4M | 10-K 2026-03-16 |
| Q3 2025 2025-09-30 | $1.1M | $200.6M | -$1.8M | $118.0M | No debt tags | $8.3M | 10-Q 2025-11-10 |
| Q2 2025 2025-06-30 | $1.3M | -$7.6M | $12.7M | $23.4M | No debt tags | $7.3M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $2.7M | $4.6M | $2.7M | $33.6M | No debt tags | $7.0M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $3.1M | $18.0M | -$30.5M | $50.5M | No debt tags | $29.6M | 10-K 2026-03-16 |
| Q3 2024 2024-09-30 | $123K | -$17.1M | -$8.4M | $131.0M | No debt tags | -$47.3M | 10-Q 2025-11-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-02-24 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.8% |
| 1 month | -41.4% |
| 3 months | -51.1% |
| Year to date | -60.8% |
| 1 year | -62.1% |
| From 52-week high | -65.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CMMB | Chemomab Therapeutics Ltd. American Depositary Share | $1.62 | +5.88% | $13.0M |
| NEUP | Neuphoria Therapeutics Inc. | $2.48 | -2.75% | $13.4M |
| OPTH | Optimi Health Corp. Common Shares | $2.15 | -4.44% | $12.3M |
| QNTM | Quantum Biopharma Ltd. Class B Subordinate Voting Shares | $1.44 | -10.56% | $12.2M |
| MRKR | Marker Therapeutics Inc. | $0.8286 | -4.76% | $13.8M |
| ALLR | Allarity Therapeutics Inc. | $0.8752 | -8.24% | $13.9M |
| LSTA | Lisata Therapeutics Inc. | $1.09 | -9.92% | $11.8M |
| MCRB | Seres Therapeutics Inc. | $1.41 | +0.71% | $14.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier